AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

App Dealroom

Published November 9, 2026

J&J backs psychedelic -inspired Delix in $100M Series C - Dealroom.co

Read the full story at App Dealroom

The pitch: a scalable, at-home alternative to both chronic standard-of-care drugs and in-clinic psychedelic therapies. Why now? Zalsupindole, inspired.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics